Cellular interaction influenced by surface modification strategies of gelatin-based nanoparticles.
Theranostic applications of gelatin nanospheres require two major components, a method of detection and good biocompatibility. We characterized the response of UTA-6 human osteosarcoma cells to the introduction of functionalized 90 bloom-based gelatin nanospheres (158 ± 49 nm) modified with three elements in different order: (a) hybridization with cadmium-based quantum dots for optical detection, (b) bioconjugation with anti-human IgG FAB (anti-IgG) for cell targeting, with/without (c) capping with polyethylene glycol on the surface for enhanced biocompatibility. A one-pot process is developed for incorporating quantum dots and antibody with gelatin nanospheres. Path A of modifying gelatin nanospheres with quantum dots first followed by anti-IgG resulted in a significantly greater cellular viability than Path B with anti-IgG first followed by quantum dots. Capping with polyethylene glycol as the final step in modification yielded significantly opposing results with decreases in Path A and increases in Path B. Three-dimensional z-stacking fluorescent images of hybrid gelatin nanospheres with anti-IgG is observed to have an increase in cellular association. The observed results suggest the modification order for building hybrid nanospheres may have an impact on cellular response.
Department of Chemical and Biochemical Engineering, Western University, London, Ontario, Canada.
Wai Hei
WH
Tse
Department of Chemical and Biochemical Engineering, Western University, London, Ontario, Canada.
Laszlo
L
Gyenis
Department of Chemical and Biochemical Engineering, Western University, London, Ontario, Canada.
David W
DW
Litchfield
Department of Chemical and Biochemical Engineering, Western University, London, Ontario, Canada.
Jin
J
Zhang
D001672:Biocompatible Materials / Q000737:chemistry*; D045744:Cell Line, Tumor; D005780:Gelatin / Q000737:chemistry*; D006801:Humans; D008422:Materials Testing; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure; D054118:Nanospheres / Q000737:chemistry* / Q000648:ultrastructure*; D009374:Neoplasms, Experimental / Q000737:chemistry* / Q000473:pathology; D010316:Particle Size; D013499:Surface Properties
D001672:Biocompatible Materials; D053769:Nanocapsules; D005780:Gelatin
Hybrid gelatin nanospheres; anti-human IgG FAB; human osteosarcoma cells; quantum dots; targeted delivery